PIM447 + ruxolitinib

**PIM447 + ruxolitinib** is an experimental combination of two targeted small molecule inhibitors: PIM447 (a pan-PIM kinase inhibitor) and ruxolitinib (a selective Janus kinase 1/2 inhibitor). Both drugs are designed to interfere with critical intracellular pathways involved in the pathogenesis of myeloproliferative neoplasms (MPNs), such as the JAK-STAT pathway and PIM kinase-related signaling. The combination is being studied for potential synergistic effects: PIM447 targets PIM kinases, involved in cell survival and cell cycle progression, thereby promoting apoptosis and cell cycle arrest; ruxolitinib inhibits JAK1/2, key mediators of aberrant cytokine signaling driving MPN. Preclinical studies suggest this doublet shows superior anti-tumor activity compared to either agent alone, with effects including reduced spleen size, tumor burden, and improved survival in animal models. The drug is under investigation, including in combination with other agents like CDK4/6 inhibitors, for enhanced efficacy in MPNs[1][2][4].